Antibiotic use in neonatal intensive care units and adherence with Centers for Disease Control and Prevention 12 Step Campaign to Prevent Antimicrobial Resistance.
BACKGROUND
The Centers for Disease Control and Prevention (CDC) 12-Step Campaign to Prevent Antimicrobial Resistance was launched to educate clinicians about antimicrobial resistance and provide strategies to improve clinical practice, including antimicrobial utilization.


METHODS
A multicenter retrospective observational study of antibiotic use was performed in 4 tertiary care NICUs to assess adherence to the guidelines defined by the CDC 12-Step Campaign using predetermined criteria. Fifty infants per NICU were identified who received intravenous antibiotics at greater than 72 hours of age. Antibiotic regimens, clinical and microbiologic data, and indications for initiation and continuation of antibiotics (after 72 hours of use) were recorded. Inappropriate utilization was characterized at initiation, continuation, by agent, and by CDC 12-Step.


RESULTS
Two hundred neonates received 323 antibiotic courses totaling 3344 antibiotic-days. Ninety (28%) courses and 806 (24%) days were judged to be nonadherent to a CDC 12-Step. Inappropriate use was more common with continuation of antibiotics (39%) than with initiation (4%) of therapy. Vancomycin was the most commonly used drug (n = 895 antibiotic-days) of which 284 (32%) days were considered inappropriate. Carbapenems were used less frequently (n = 310 antibiotic-days), and 132 (43%) of these days were inappropriate. Common reasons for nonadherence at the time of continuation included failure to narrow antibiotic coverage after microbiologic results were known and prolonged antibiotic prophylaxis after surgery with chest tube placement.


CONCLUSIONS
The CDC 12-Step Campaign can be modified for neonatal populations. Inappropriate antibiotic prescribing was common in the study NICUs. Improvement efforts should target antibiotic use 72 hours after initiation, particularly focusing on narrowing therapy and instituting protocols to limit prophylaxis.
Patel
Sameer J
SJ
Division of Infectious Diseases, Department of Pediatrics, Columbia University, New York, NY, USA. sp2172@columbia.edu
Oshodi
Adebayo
A
Prasad
Priya
P
Delamora
Patricia
P
Larson
Elaine
E
Zaoutis
Theoklis
T
Paul
David A
DA
Saiman
Lisa
L
D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D002487:Centers for Disease Control and Prevention, U.S.; D003428:Cross Infection / Q000188:drug therapy / Q000517:prevention & control; D024881:Drug Resistance, Bacterial; D005260:Female; D019983:Guideline Adherence; D006801:Humans; D007231:Infant, Newborn; D019102:Infant, Very Low Birth Weight; D007363:Intensive Care Units, Neonatal / Q000592:standards*; D008297:Male; D012189:Retrospective Studies; D014481:United States
D000900:Anti-Bacterial Agents